Month: August 2024

EuroDry Ltd. Reports Results for the Six-Month Period and Quarter Ended June 30, 2024

Written by Customer Service on August 8, 2024. Posted in Earnings Releases And Operating Results.

ATHENS, Greece, Aug. 08, 2024 (GLOBE NEWSWIRE) — EuroDry Ltd. (NASDAQ: EDRY, the “Company” or “EuroDry”), an owner and operator of drybulk vessels and provider of seaborne transportation for drybulk cargoes, announced today its results for the three and six month periods ended June 30, 2024. Second Quarter 2024 Highlights:Total net revenues for the quarter of $17.4 million.Net loss attributable to controlling shareholders, of $0.41 million or $0.15 loss per share basic and diluted, respectively.Adjusted net loss1 attributable to controlling shareholders for the quarter of $0.45 million or $0.17 loss per share basic and diluted, respectively, before unrealized gain on derivatives.Adjusted EBITDA1 for the quarter was $5.0 million.An average of 13.0 vessels were owned and operated during the second quarter of 2024 earning...

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

Written by Customer Service on August 8, 2024. Posted in Earnings Releases And Operating Results.

– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature Medicine and featured at ASCO 2024 – – Announced 54% complete response (CR) rate in the intention-to-treat population at 24-month landmark and meets primary endpoint in the CORE-001 study – – Demonstrated 75.2% CR rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in Cretostimogene Monotherapy BOND-003 study – – Initiated and dosed first patient in Expanded Access Program for Cretostimogene Grenadenorepvec; Enrollment ongoing – IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential...

Biopesticides Market to Reach USD 21.81 Billion by 2031, Growing at 15.9% CAGR | SkyQuest Technology

Written by Customer Service on August 8, 2024. Posted in Mergers And Acquisitions.

Westford, USA, Aug. 08, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Biopesticides Market will attain a value of USD 21.81 billion by 2031, with a CAGR of 15.9% over the forecast period (2024-2031). Growing adoption of sustainable farming practices and imposition of stringent regulations to reduce the use of chemicals in farming are slated to drive biopesticide sales. Increasing emphasis on sustainability and growing demand for organic food products by consumers around the world will also favor sales of biopesticides. Download a detailed overview:https://www.skyquestt.com/sample-request/biopesticides-market Browse in-depth TOC on “Biopesticides Market” Pages – 158 Tables – 145 Figures – 78Biopesticides Market Overview:Report Coverage DetailsMarket Revenue in 2023 $ 6.7 billionEstimated...

Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Written by Customer Service on August 8, 2024. Posted in Earnings Releases And Operating Results.

THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling $255.3 million as of June 30, 2024 SAN FRANCISCO, Aug. 08, 2024 (GLOBE NEWSWIRE) — Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the second quarter June 30, 2024, along with business updates. “We are making excellent progress in our Phase 1 SAD/MAD clinical trial of THB335 and now expect to report clinical results during the first quarter of 2025,” said Natalie Holles, Chief Executive Officer at Third Harmonic Bio. “In parallel with conduct of this ongoing clinical trial,...

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

Written by Customer Service on August 8, 2024. Posted in Public Companies.

COPENHAGEN, Denmark, Aug. 08, 2024 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is proud to announce the presentation of one-year clinical efficacy Phase 2 data for its lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2024, taking place in Barcelona, Spain, from September 13-17, 2024. The EVX-01 vaccine is a personalized therapy currently being assessed in patient with advanced melanoma (skin cancer). Christian Kanstrup, CEO of Evaxion, comments: “Having our abstract selected for presentation by the ESMO Congress 2024 Scientific Committee is a testament to the significant progress and impact of our work in the field of medical oncology. This is one of the most prestigious medical...

Mobivity Schedules Second Quarter 2024 Conference Call for Wednesday, August 14, 2024

Written by Customer Service on August 8, 2024. Posted in Public Companies.

PHOENIX, Aug. 08, 2024 (GLOBE NEWSWIRE) — Mobivity Holdings Corp. (OTCQB: MFON), a provider of technology connecting mobile gaming audiences to real-world brands and products, today announced that it has scheduled its conference call to announce results for the second quarter ended June 30, 2024 on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time. The company plans to release results for the second quarter ended June 30, 2024 on Wednesday, August 14th, after the markets close. Conference Call Information: Date: Wednesday, August 14, 2024Time: 4:30 p.m. Eastern Time Dial in Number for U.S. Callers: 1-800-717-1738Dial in Number for International Callers: 1-646-307-1865Please Reference Conference ID: 66124 The call will also be accompanied live by webcast over the Internet and accessible at https://viavid.webcasts.com/starthere.jsp?ei=1683931&tp_key=b48ebcc8ae. To...

red violet to Participate in the Midwest IDEAS Investor Conference

Written by Customer Service on August 8, 2024. Posted in Public Companies.

BOCA RATON, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) — Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, today announced that it will participate in the Midwest IDEAS Investor Conference being held in Chicago on August 29, 2024. Derek Dubner, Chief Executive Officer, and Daniel MacLachlan, Chief Financial Officer, will present and host investor meetings. About red violet®At red violet, we build proprietary technologies and apply analytical capabilities to deliver identity intelligence. Our technology powers critical solutions, which empower organizations to operate with confidence. Our solutions enable the real-time identification and location of people, businesses, assets and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due...

Crown LNG Appoints Andrew Judson as Chairman of the Board

Written by Customer Service on August 8, 2024. Posted in Public Companies.

ST HELIER, Jersey, Aug. 08, 2024 (GLOBE NEWSWIRE) — Crown LNG Holdings Limited (NASDAQ: CGBS) (“Crown” or “Crown LNG”), a leading provider of LNG liquefaction and regasification terminal technologies for harsh weather locations, today announced that its Board of Directors has appointed Andrew Judson to serve as Chairman of the Board, effective August 2, 2024. Mr. Judson takes over the role previously held by Jørn Husemoen, who will continue to serve as a member of the Board and Crown LNG’s Chief Financial Officer. Mr. Judson, who has served as an independent director of Crown’s Board since July 2024, possesses a wealth of experience in the finance and energy sectors. He currently serves as a Senior Advisor at Fort Capital, one of Canada’s leading independent investment banking advisory firms. Prior to joining Fort Capital, Mr....

Rumble’s Founder and CEO Chris Pavlovski to Hold a Post-Earnings Live Stream with Matt Kohrs via Rumble Studio

Written by Customer Service on August 8, 2024. Posted in Public Companies.

LONGBOAT KEY, FL, Aug. 08, 2024 (GLOBE NEWSWIRE) — Rumble Inc. (NASDAQ: RUM), the video-sharing platform and cloud services provider, announced today that Chris Pavlovski, the Chairman and CEO of Rumble, will be interviewed by Matt Kohrs on Monday, August 12, 2024, shortly after the earnings call. The interview will be streamed live on the Matt Kohrs Rumble channel at rumble.com/MattKohrs using Rumble’s streaming platform, Rumble Studio. Viewers will be able to submit questions to Mr. Pavlovski in the comments section of the live stream. Mr. Pavlovski’s interview with Matt Kohrs will focus on Rumble’s second quarter 2024 accomplishments and future initiatives and will follow Rumble’s release of its second quarter 2024 earnings results. As previously announced, Rumble’s earnings call is scheduled for 5:00 p.m. Eastern Time on Monday,...

Acorn’s Q2’24 EPS Improves to $0.11 vs. $0.04 on Revenue Increase in Remote Monitoring and Control Solutions for Backup Power Generators

Written by Customer Service on August 8, 2024. Posted in Earnings Releases And Operating Results.

Investor Call Today at 11am ET; Dial-in: 1-844-834-0644 WILMINGTON, Del., Aug. 08, 2024 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (OTCQB: ACFN) (Acorn), a provider of remote monitoring and control solutions for backup power generators, gas pipelines, air compressors and other mission critical assets, announced results for its second quarter ended June 30, 2024 (Q2’24) and will hold an investor call today at 11am ET (see call details below).Summary Financial Results ($ in thousands) Q2’24 Q2’23 Change 6M’24 6M’23 Change Monitoring revenue $ 1,110 $ 1,065 +4.2 % $ 2,212 $ 2,089 +5.9 %Hardware revenue $ 1,165 $ 908 +28.3 % $ 2,195 $ 1,633 +34.4 %Total revenue (1) $ 2,275 $ 1,973 +15.3 % $ 4,407 $ 3,722 +18.4 %Gross margin 73.2 % 75.5 % 73.9 % 75.4 % Net...

Month: August 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals